Biosergen AS
Research Biosergen AS (BIOSGN) on Bullrun: market cap SEK 50.60M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBIOSGN
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 50.60M
- Financial periodFY2025
- RevenueSEK 0
- Net income-SEK 40.82M
- Free cash flow-SEK 35.53M
Valuation Snapshot
latest market cap is SEK 50.60M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 40.82M | -SEK 35.53M | n/a | -17.31 | SEK 15.37M | n/a | SEK 8.12M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | SEK 50.60M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Biosergen AS
Biosergen AB (publ), a biotech company, develops antifungal drugs. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Biosergen AS's market cap?
Biosergen AS's market capitalization is SEK 50.60M.
What does Biosergen AS do?
Biosergen AB (publ), a biotech company, develops antifungal drugs. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.